Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1969 2
1970 2
1971 2
1972 4
1973 3
1974 6
1975 5
1977 6
1978 3
1979 1
1980 3
1982 5
1983 3
1984 2
1986 2
1987 2
1988 2
1989 3
1990 9
1991 4
1992 1
1993 5
1994 11
1995 7
1996 9
1997 14
1998 17
1999 17
2000 18
2001 14
2002 21
2003 45
2004 54
2005 58
2006 74
2007 62
2008 91
2009 83
2010 103
2011 161
2012 173
2013 157
2014 153
2015 166
2016 187
2017 158
2018 197
2019 151
2020 171
2021 94
2022 11
2023 5
2024 137
2025 98

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,530 results

Results by year

Filters applied: . Clear all
Page 1
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F; PURPOSE 1 Study Team. Bekker LG, et al. N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. Epub 2024 Jul 24. N Engl J Med. 2024. PMID: 39046157 Clinical Trial.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. Tam CS, et al. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. Blood. 2020. PMID: 32731259 Free PMC article. Clinical Trial.
HIV Pre-Exposure Prophylaxis.
Liegeon G, Delaugerre C, Molina JM. Liegeon G, et al. Infect Dis Clin North Am. 2024 Sep;38(3):453-474. doi: 10.1016/j.idc.2024.04.003. Epub 2024 Jun 12. Infect Dis Clin North Am. 2024. PMID: 38871567 Review.
Bictegravir.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Curr Opin HIV AIDS. 2018. PMID: 29746268 Review.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J; IMPAACT 2010/VESTED Study Team and Investigators. Lockman S, et al. Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7. Lancet. 2021. PMID: 33812487 Free PMC article. Clinical Trial.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Venter WDF, et al. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.
2,530 results